Se connecter S'abonner en ligne
  • Infos sociétés
  • Infos OPCVM
  • Alertes e-mail
  • Notre offre
 Langues  Par thème  Par secteur d'activité  Par pays
WEX Pharmaceuticals Inc. [0]   
[11/12/2023]

WEX Pharmaceuticals Inc. : Wex Pharmaceuticals Inc. Commences Its Quantitative Sensory Testing Clinical Trial Evaluating the Impact of Halneuron(R) on Healthy Volunteers’ Sensory Perceptions

VANCOUVER, BC / ACCESSWIRE / December 11, 2023 / WEX Pharmaceuticals Inc. "WEX" or the "Company", a biotechnology company developing Halneuron® Tetrodotoxin or TTX for pain, announced that it has commenced its Quantitative Sensory Testing QST clinical trial and is actively recruiting participants into this clinical trial. The QST clinical trial is being conducted in the... Lire le communiqué
 
WEX Pharmaceuticals Inc. [0]   
[03/01/2023]

WEX Pharmaceuticals Inc. : Wex Pharmaceuticals Inc. Enrolls the First Patient in The Phase 2b Clinical Trial Evaluating the Efficacy and Safety of Halneuron(R) In the Treatment of Chemotherapy-Induced Neuropathic Pain

VANCOUVER, BC / ACCESSWIRE / January 3, 2023 / WEX Pharmaceuticals Inc. "WEX" or the "Company", a biotechnology company developing Halneuron® Tetrodotoxin or TTX for pain, announced that the first patient has been dosed in its Phase 2B clinical trial evaluating the efficacy and safety of Tetrodotoxin in the treatment of ChemotherapyInduced Neuropathic Pain the... Lire le communiqué
 


Vidéos
Gestionnaires,
Emetteurs,
Ma sélection
Les communiqués les plus lus de WEX Pha...